Margaret Hamburg, M.D.
Co-president, InterAcademy Partnership
Margaret A. Hamburg, MD, Joins NTI as Interim Vice President for NTI | bio
NTI board member Margaret A. Hamburg, MD, is joining NTI’s leadership to serve as interim vice president of the NTI | bio program in February. Hamburg, an internationally recognized leader in public health and medicine, replaces Beth Cameron, PhD, who has moved to the White House to rebuild the National Security Council’s Office of Global Health Security and Biodefense and advance the Biden Administration’s agenda on global health security.
Hamburg’s relationship with NTI goes back to its launch in 2001, when she was named as the organization’s founding senior scientist and biological program vice president. She went on to become commissioner of the Food and Drug Administration and foreign secretary of the National Academy of Medicine.
Hamburg joined NTI’s Board of Directors in 2017.
Stay Informed
Sign up for our newsletter to get the latest on nuclear and biological threats.
More News
U.S. and Chinese Experts Find Common Ground on Guardrails for AI in Biology
NTI | bio and the Center for International Security and Strategy (CISS) at Tsinghua University convened a virtual dialogue on risks at the convergence of artificial intelligence and the life sciences (AIxBio).
85% of Registered Voters Support the United States Working with China to Mitigate AI Risks, according to New Poll
New YouGov polling commissioned by NTI and ReThink Media finds that nearly 80 percent of registered voters, across party lines, say it is in the interest of U.S. national security to work with China to mitigate catastrophic threats associated with nuclear risks, AI development, and bioterrorism.
NTI, Concordia AI Launch International Working Group to Improve Biological Capability Evaluations
NTI | bio and Concordia AI, with technical input from SecureBio, have launched the AIxBio Technical Working Group on Evaluation Practice. Convened through the AIxBio Global Forum, the Working Group will bring together experts from organizations in China, the European Union, the United Kingdom, and the United States that develop or conduct biological capability evaluations of AI systems.
